SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dbuki who wrote (10134)10/25/1997 9:45:00 PM
From: Andrew H  Read Replies (1) | Respond to of 32384
 
>>Since you are affiliated with Metabolex, a biotech company concentrating on diabetes, there may be some conflict of interest which undermines the credibility of your depreciative remarks about LGND.<<

This joker has no credibility to undermine! But your point is well taken. If he is affiliated with Metabolex, we can surely make a lot of money shorting that stock. I cannot believe they are associated with people who spread such blatant misinformation. One can only hope he is ignorant and not intentionally attempting to mislead.



To: dbuki who wrote (10134)10/25/1997 9:58:00 PM
From: james  Read Replies (2) | Respond to of 32384
 
dbuki. Thanks for the comment!

I've recommended LNGD 6 months ago to a very close friend at 12 1/2. But not now. Because I read their paper published in Nature in April describing the mice tests. Acturally, it was quite unusual for a small biotech Co. to go public so early with such a major development. People tend to hide it till after the start of phase I. They even put the chemical structure in print!!!!!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News